22.11.2013

TiGenix completes EUR 12 million capital increase with strategic investor Grifols

Leuven, Belgium – November 22, 2013, 12.15 p.m. – TiGenix NV (Euronext Brussels: TIG) announced today the successful completion of the EUR 12 million capital increase announced on November 20, 2013. In total, 34.188.034 new ordinary shares were issued to Gri-Cel S.A., a fully-owned subsidiary of global healthcare company Grifols S.A. TiGenix will prepare and, after approval by the FSMA, publish a prospectus regarding the admittance of the new shares to trading on NYSE Euronext Brussels, which is expected to take place in the following weeks.

The total number of outstanding ordinary shares in TiGenix NV as of November 22, 2013 amounts to 160,476,620.

“This is a very important milestone for the company. We are delighted to have attracted Grifols as a long-term strategic investor and potential partner,” said Eduardo Bravo, CEO of TiGenix. “The funds allow us to continue to fully focus on the completion of the Phase III trial with our lead product Cx601, and to strengthen our commercial operations and the further roll-out of ChondroCelect. Having such a reference shareholder increases our financial stability and strengthens our position for future partnering negotiations with third parties.”

“The investment in TiGenix clearly demonstrates Grifols’ commitment to enter the field of advanced therapies and personalized medicine, as well as its dedication to innovative therapeutic approaches. I believe there is no better way to do so than by investing in one of the global leaders in the field of mesenchymal stem cell therapy,” said Dirk Büscher, CEO of Gri-Cel. “For Grifols this is a strategic investment with a long-term perspective, combined with the strong belief in the technologies that have been and are being developed by TiGenix. There is also the hope for additional future fruitful collaborations with TiGenix taking advantage of the magnitude of Grifols’ pipeline and products.”

For more information:

Eduardo Bravo
Chief Executive
eduardo.bravo@tigenix.com

Claudia D’Augusta
Officer Chief Financial Officer
claudia.daugusta@tigenix.com

Hans Herklots
Director Investor & Media Relations
hans.herklots@tigenix.com
+32 16 39 60 97

About TiGenix

TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy company with a marketed cell therapy product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.

About Grifols
Grifols is a global healthcare company with a 70-year legacy of improving people’s health and well being through the development of life-saving plasma medicines, hospital pharmacy products and diagnostic technology for clinical use. 

As a leading producer of plasma medicines, Grifols has a presence in more than 100 countries and is the world leader in plasma collection, with 150 plasma donation centers across the U.S. Grifols is committed to increasing patient access to its life-saving plasma medicines through significant manufacturing expansions and the development of new therapeutic applications of plasma proteins. The company is headquartered in Barcelona, Spain and employs more than 11,000 people worldwide.

In 2012, Grifols’ sales exceeded €2,620 billion. The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information visit www.grifols.com.

Forward-looking information
This press release is for information purposes only and is not intended to constitute, and should not be construed as, an offer to sell or a solicitation of any offer to buy shares in the share capital of TiGenix NV (the “Company”). This announcement has been issued by and is the sole responsibility of the Company.

Certain statements in this press release, as well as oral statements that may be made by the Company or by officers, directors or employees acting on their behalf relating to the subject matter hereof, may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. Forward-looking statements may be identified by references to strategy, plans, objectives, goals, future events or intentions. Forward-looking statements involve a number of known and unknown risks, uncertainties and other factors, many of which are difficult to predict and generally beyond the control of the Company. Forward looking statements may and often do differ materially from actual results. The Company therefore cannot provide any assurance that such forwardlooking statements will materialize. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. Forward-looking statements speak only as of the date they are made. The Company expressly disclaims any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise.


Download

Download pdf English
Download pdf Spanish